Uploaded April 2025 | Updated September 2026, 1 hour ago
CAR-T cell therapy has shown remarkable promise in treating autoimmune diseases by effectively “resetting” the immune system—improving patient outcomes and reducing the need for lifelong immunosuppressive drugs. However, traditional CAR-T therapies require lymphodepletion, a chemotherapy-based process that can lead to significant side effects and limit accessibility.
At the Calibr-Skaggs Institute of Scripps Research, we are advancing a novel “switchable” CAR-T platform designed to eliminate the need for lymphodepletion. This approach may significantly reduce treatment-related toxicity and broaden the availability of CAR-T therapy to a wider patient population.
Our upcoming phase 1 clinical trial will evaluate the safety and efficacy of our switchable CAR-T cell therapy (CLBR001) and antibody switch (SWI019) in patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis—with the potential to expand into additional indications in the future.
For more information on our platform and approach, please visit: https://calibr.scripps.edu/our-pipeline/scar-t/
CAR-T cell therapy has shown remarkable promise in treating autoimmune diseases by effectively “resetting” the immune system—improving patient outcomes and reducing the need for lifelong immunosuppressive drugs. However, traditional CAR-T therapies require lymphodepletion, a chemotherapy-based process that can lead to significant side effects and limit accessibility.
At the Calibr-Skaggs Institute of Scripps Research, we are advancing a novel “switchable” CAR-T platform designed to eliminate the need for lymphodepletion. This approach may significantly reduce treatment-related toxicity and broaden the availability of CAR-T therapy to a wider patient population.
Our upcoming phase 1 clinical trial will evaluate the safety and efficacy of our switchable CAR-T cell therapy (CLBR001) and antibody switch (SWI019) in patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis—with the potential to expand into additional indications in the future.
For more information on our platform and approach, please visit: https://calibr.scripps.edu/our-pipeline/scar-t/
